{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:10:22Z","timestamp":1790165422319,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971616"],"award-info":[{"award-number":["81971616"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Medical and Health Science and Technology Innovation Project of Chinese Academy of Medical Sciences","award":["2021-I2M-C&T-B-065"],"award-info":[{"award-number":["2021-I2M-C&T-B-065"]}]},{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2020B19"],"award-info":[{"award-number":["LC2020B19"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol Exp"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We evaluated the early changes in left ventricular (LV) volumetric, functional, and tissue characteristics in human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients treated with trastuzumab and\/or pertuzumab at cardiac magnetic resonance imaging (MRI).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>HER2-positive breast cancer patients undergoing planned anti-HER2 therapy and nonanthracycline-based chemotherapy were enrolled and subdivided into dual anti-HER2 (trastuzumab plus pertuzumab) group and trastuzumab group. Cardiac MRI was performed before treatment and three months after starting, covering ventricular volumes, cardiac function, systolic myocardial strain, myocardial oedema, and T1 and T2 relaxation times. Cardiac dysfunction was primarily defined as a\u2009&gt;\u200910% reduction in LV ejection fraction (LVEF) to\u2009&lt;\u200955% and\/or a\u2009&gt;\u200915% global longitudinal strain (GLS) change at the follow-up MRI examination.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-four HER2-positive patients were evaluated (16 in the dual anti-HER2 group, 8 in the trastuzumab group). Six patients developed cardiac dysfunction at follow-up, five of them in the dual anti-HER2 group. One patient developed symptomatic heart failure, and five patients developed asymptomatic cardiac dysfunction. Patients displayed significantly decreased systolic function and increased T1 and T2 relaxation time at follow-up (<jats:italic>p<\/jats:italic>\u2009\u2264\u20090.031). Systolic dysfunction remained significant in the dual anti-HER2 group. The decrease in GLS in the trastuzumab group was not significant (<jats:italic>p<\/jats:italic>\u2009=\u20090.169). T1 and T2 relaxation times tended to increase, but this was not significant at subgroup analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Cardiac MRI scans showed frequent signs of subclinical cardiotoxicity after short-term anti-HER2 therapy and nonanthracycline-based chemotherapy; the effect was slightly stronger in patients treated with dual therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key points<\/jats:title>\n                <jats:p>\u2022 A frequent subclinical cardiotoxicity was detected by cardiac magnetic resonance imaging after short-term anti-human epidermal growth factor receptor 2 (HER2) therapy.<\/jats:p>\n                <jats:p>\u2022 The change in myocardial strain was more marked in patients treated with dual (trastuzumab plus pertuzumab) than with trastuzumab only anti-HER2 therapy.<\/jats:p>\n                <jats:p>\u2022 Cardiotoxicity surveillance through MRI is an interesting option particularly in patients treated with dual anti-HER2 therapy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41747-023-00338-9","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:19:50Z","timestamp":1684160390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Longitudinal assessment of cardiac parameters through MRI in breast cancer patients treated with anti-HER2 therapy"],"prefix":"10.1186","volume":"7","author":[{"given":"Sainan","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9511-0952","authenticated-orcid":false,"given":"Jianwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linlin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenglan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"338_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Cort\u00e9s J, Kim S-B et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119. https:\/\/doi.org\/10.1056\/NEJMoa1113216","journal-title":"N Engl J Med"},{"key":"338_CR2","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-18-3003","volume":"25","author":"LJ Howie","year":"2019","unstructured":"Howie LJ, Scher NS, Amiri-Kordestani L et al (2019) FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 25:2949\u20132955. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3003","journal-title":"Clin Cancer Res"},{"key":"338_CR3","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41569-020-0348-1","volume":"17","author":"J Herrmann","year":"2020","unstructured":"Herrmann J (2020) Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol 17:474\u2013502. https:\/\/doi.org\/10.1038\/s41569-020-0348-1","journal-title":"Nat Rev Cardiol"},{"key":"338_CR4","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS et al (2022) 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J Cardiovasc Imaging 23:e333\u2013e465. https:\/\/doi.org\/10.1093\/ehjci\/jeac106","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"338_CR5","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1111\/echo.15190","volume":"38","author":"A Banke","year":"2021","unstructured":"Banke A, Schou M, Ewertz M et al (2021) Immediate evaluation of global longitudinal strain at initiation of trastuzumab treatment in breast cancer patients. Echocardiography 38:1702\u20131710. https:\/\/doi.org\/10.1111\/echo.15190","journal-title":"Echocardiography"},{"key":"338_CR6","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1016\/j.jcmg.2020.09.039","volume":"14","author":"CP Houbois","year":"2021","unstructured":"Houbois CP, Nolan M, Somerset E et al (2021) Serial cardiovascular magnetic resonance strain measurements to identify cardiotoxicity in breast cancer: comparison with echocardiography. JACC Cardiovasc Imaging 14:962\u2013974. https:\/\/doi.org\/10.1016\/j.jcmg.2020.09.039","journal-title":"JACC Cardiovasc Imaging"},{"key":"338_CR7","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1200\/JCO.21.01736","volume":"40","author":"H Greenlee","year":"2022","unstructured":"Greenlee H, Iribarren C, Rana JS et al (2022) Risk of cardiovascular disease in women with and without breast cancer: the pathways heart study. J Clin Oncol 40:1647\u20131658. https:\/\/doi.org\/10.1200\/JCO.21.01736","journal-title":"J Clin Oncol"},{"key":"338_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK et al (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:1215\u20131221. https:\/\/doi.org\/10.1200\/JCO.2002.20.5.1215","journal-title":"J Clin Oncol"},{"key":"338_CR9","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JC Plana","year":"2014","unstructured":"Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063\u20131093. https:\/\/doi.org\/10.1093\/ehjci\/jeu192","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"338_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.jcmg.2019.10.016","volume":"13","author":"MA Altaha","year":"2020","unstructured":"Altaha MA, Nolan M, Marwick TH et al (2020) Can quantitative CMR tissue characterization adequately identify cardiotoxicity during chemotherapy? JACC Cardiovasc Imaging 13:951\u2013962. https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.016","journal-title":"JACC Cardiovasc Imaging"},{"key":"338_CR11","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano JL, Lancellotti P, Rodriguez Munoz D et al (2016) 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37:2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"Eur Heart J"},{"key":"338_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.cardfail.2011.10.015","volume":"18","author":"L Tarantini","year":"2012","unstructured":"Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer. J Card Fail 18:113\u2013119. https:\/\/doi.org\/10.1016\/j.cardfail.2011.10.015","journal-title":"J Card Fail"},{"key":"338_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12947-021-00266-x","volume":"19","author":"NI Bouwer","year":"2021","unstructured":"Bouwer NI, Liesting C, Kofflard MJM et al (2021) 2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab. Cardiovasc Ultrasound 19:35. https:\/\/doi.org\/10.1186\/s12947-021-00266-x","journal-title":"Cardiovasc Ultrasound"},{"key":"338_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1001\/jamacardio.2021.5881","volume":"7","author":"M Esmaeilzadeh","year":"2022","unstructured":"Esmaeilzadeh M, Urzua Fresno CM, Somerset E et al (2022) A combined echocardiography approach for the diagnosis of cancer therapy-related cardiac dysfunction in women with early-stage breast cancer. JAMA Cardiol 7:330\u2013340. https:\/\/doi.org\/10.1001\/jamacardio.2021.5881","journal-title":"JAMA Cardiol"},{"key":"338_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S et al (2022) Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J 43:280\u2013299. https:\/\/doi.org\/10.1093\/eurheartj\/ehab674","journal-title":"Eur Heart J"},{"key":"338_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s10549-018-5058-6","volume":"174","author":"E Lidbrink","year":"2019","unstructured":"Lidbrink E, Chmielowska E, Otremba B et al (2019) A real-world study of cardiac events in > 3700 patients with HER2-positive early breast cancer treated with trastuzumab: final analysis of the OHERA study. Breast Cancer Res Treat 174:187\u2013196. https:\/\/doi.org\/10.1007\/s10549-018-5058-6","journal-title":"Breast Cancer Res Treat"},{"key":"338_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","volume":"4","author":"T Omland","year":"2022","unstructured":"Omland T, Heck SL, Gulati G (2022) The role of cardioprotection in cancer therapy cardiotoxicity: JACC: CardioOncology state-of-the-art review. JACC CardioOncol 4:19\u201337. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.101","journal-title":"JACC CardioOncol"},{"key":"338_CR18","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter C, Nielsen TH, Edfors LR et al (2022) A systematic review and meta-analysis of beta-blockers and renin\u2013angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J 43:2562\u20132569. https:\/\/doi.org\/10.1093\/eurheartj\/ehab843","journal-title":"Eur Heart J"},{"key":"338_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S et al (2017) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35:870\u2013877. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830","journal-title":"J Clin Oncol"},{"key":"338_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s10554-018-1482-2","volume":"35","author":"IY Gong","year":"2019","unstructured":"Gong IY, Ong G, Brezden-Masley C et al (2019) Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. Int J Cardiovasc Imaging 35:653\u2013662. https:\/\/doi.org\/10.1007\/s10554-018-1482-2","journal-title":"Int J Cardiovasc Imaging"},{"key":"338_CR21","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.amjcard.2018.12.046","volume":"123","author":"L Song","year":"2019","unstructured":"Song L, Brezden-Masley C, Ramanan V et al (2019) Serial measurements of left ventricular systolic and diastolic function by cardiac magnetic resonance imaging in patients with early stage breast cancer on trastuzumab. Am J Cardiol 123:1173\u20131179. https:\/\/doi.org\/10.1016\/j.amjcard.2018.12.046","journal-title":"Am J Cardiol"},{"key":"338_CR22","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1634\/theoncologist.2014-0500","volume":"20","author":"JM Serrano","year":"2015","unstructured":"Serrano JM, Gonzalez I, Del Castillo S et al (2015) Diastolic dysfunction following anthracycline-based chemotherapy in breast cancer patients: incidence and predictors. Oncologist 20:864\u2013872. https:\/\/doi.org\/10.1634\/theoncologist.2014-0500","journal-title":"Oncologist"},{"key":"338_CR23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaccao.2021.12.002","volume":"4","author":"G Minotti","year":"2022","unstructured":"Minotti G, Reggiardo G, Camilli M, Salvatorelli E, Menna P (2022) From cardiac anthracycline accumulation to real-life risk for early diastolic dysfunction: a translational approach. JACC CardioOncol 4:139\u2013140. https:\/\/doi.org\/10.1016\/j.jaccao.2021.12.002","journal-title":"JACC CardioOncol"},{"key":"338_CR24","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","volume":"7","author":"JH Jordan","year":"2014","unstructured":"Jordan JH, D\u2019Agostino RB Jr, Hamilton CA et al (2014) Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance. Circ Cardiovasc Imaging 7:872\u2013879. https:\/\/doi.org\/10.1161\/CIRCIMAGING.114.002217","journal-title":"Circ Cardiovasc Imaging"},{"key":"338_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","volume":"26","author":"K Negishi","year":"2013","unstructured":"Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493\u2013498. https:\/\/doi.org\/10.1016\/j.echo.2013.02.008","journal-title":"J Am Soc Echocardiogr"},{"key":"338_CR26","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","volume":"3","author":"MM Alhussein","year":"2021","unstructured":"Alhussein MM, Mokbel A, Cosman T et al (2021) Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. CJC Open 3:1372\u20131382. https:\/\/doi.org\/10.1016\/j.cjco.2021.06.019","journal-title":"CJC Open"},{"key":"338_CR27","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","volume":"73","author":"C Gal\u00e1n-Arriola","year":"2019","unstructured":"Gal\u00e1n-Arriola C, Lobo M, V\u00edlchez-Tschischke JP et al (2019) Serial magnetic resonance imaging to identify early stages of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 73:779\u2013791. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.046","journal-title":"J Am Coll Cardiol"},{"key":"338_CR28","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"J Celutkiene","year":"2020","unstructured":"Celutkiene J, Pudil R, Lopez-Fernandez T et al (2020) Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail 22:1504\u20131524. https:\/\/doi.org\/10.1002\/ejhf.1957","journal-title":"Eur J Heart Fail"},{"key":"338_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2015-0230","volume":"21","author":"SC Seferina","year":"2016","unstructured":"Seferina SC, de Boer M, Derksen MW et al (2016) Cardiotoxicity and cardiac monitoring during adjuvant trastuzumab in daily dutch practice: a study of the southeast netherlands breast cancer consortium. Oncologist 21:555\u2013562. https:\/\/doi.org\/10.1634\/theoncologist.2015-0230","journal-title":"Oncologist"},{"key":"338_CR30","doi-asserted-by":"publisher","unstructured":"Feher A, Baldassarre LA, Sinusas AJ (2022) Novel cardiac computed tomography methods for the assessment of anthracycline induced cardiotoxicity. Front Cardiovasc Med 9:875150. https:\/\/doi.org\/10.3389\/fcvm.2022.875150","DOI":"10.3389\/fcvm.2022.875150"},{"key":"338_CR31","doi-asserted-by":"publisher","unstructured":"Wang R, Fang Z, Wang H et al (2021) Quantitative analysis of three-dimensional left ventricular global strain using coronary computed tomography angiography in patients with heart failure: comparison with 3T cardiac MR. Eur J Radiol 135:109485. https:\/\/doi.org\/10.1016\/j.ejrad.2020.109485","DOI":"10.1016\/j.ejrad.2020.109485"},{"key":"338_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jaccao.2020.05.007","volume":"2","author":"A Feher","year":"2020","unstructured":"Feher A, Boutagy NE, Stendahl JC et al (2020) Computed tomographic angiography assessment of epicardial coronary vasoreactivity for early detection of doxorubicin-induced cardiotoxicity. JACC CardioOncol 2:207\u2013219. https:\/\/doi.org\/10.1016\/j.jaccao.2020.05.007","journal-title":"JACC CardioOncol"},{"key":"338_CR33","doi-asserted-by":"publisher","unstructured":"Posch F, Niedrist T, Glantschnig T et al (2022) Left ventricular ejection fraction and cardiac biomarkers for dynamic prediction of cardiotoxicity in early breast cancer. Front Cardiovasc Med 9:933428. https:\/\/doi.org\/10.3389\/fcvm.2022.933428","DOI":"10.3389\/fcvm.2022.933428"}],"container-title":["European Radiology Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-023-00338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41747-023-00338-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41747-023-00338-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:21:02Z","timestamp":1684160462000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurradiolexp.springeropen.com\/articles\/10.1186\/s41747-023-00338-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["338"],"URL":"https:\/\/doi.org\/10.1186\/s41747-023-00338-9","relation":{},"ISSN":["2509-9280"],"issn-type":[{"value":"2509-9280","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was approved by the institutional review board of the National Cancer Center, Beijing, China (No. NCC2020C-508), and all study participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Two of the authors (YF and LX) work for GE Heathcare China. The remaining authors of this article declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}